ATE556719T1 - Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält - Google Patents

Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält

Info

Publication number
ATE556719T1
ATE556719T1 AT10003160T AT10003160T ATE556719T1 AT E556719 T1 ATE556719 T1 AT E556719T1 AT 10003160 T AT10003160 T AT 10003160T AT 10003160 T AT10003160 T AT 10003160T AT E556719 T1 ATE556719 T1 AT E556719T1
Authority
AT
Austria
Prior art keywords
influenza
epitopes
human
peptides
epitope
Prior art date
Application number
AT10003160T
Other languages
English (en)
Inventor
Ruth Arnon
Tamar Ben-Yedidia
Raphael Levi
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE556719T1 publication Critical patent/ATE556719T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT10003160T 1998-11-30 1999-11-28 Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält ATE556719T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza

Publications (1)

Publication Number Publication Date
ATE556719T1 true ATE556719T1 (de) 2012-05-15

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10003160T ATE556719T1 (de) 1998-11-30 1999-11-28 Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält

Country Status (15)

Country Link
US (3) US6740325B1 (de)
EP (2) EP1135159A2 (de)
JP (1) JP2002531415A (de)
KR (1) KR100703571B1 (de)
AT (1) ATE556719T1 (de)
AU (1) AU766883B2 (de)
BR (1) BR9915811A (de)
CA (1) CA2352454C (de)
DK (1) DK2204187T3 (de)
ES (1) ES2389611T3 (de)
HK (2) HK1040620A1 (de)
IL (3) IL127331A0 (de)
NZ (1) NZ511918A (de)
PT (1) PT2204187E (de)
WO (1) WO2000032228A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU2002223398A1 (en) * 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
ES2392891T3 (es) 2003-11-04 2012-12-14 The Administrators Of The Tulane Educational Fund Procedimiento de prevención de la fusión virus célula inhibiendo la función de la región de iniciación de fusión de virus de ARN que tienen proteínas de envoltura fusogénicas de membrana de clase I
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
JP2008526870A (ja) * 2005-01-05 2008-07-24 フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン 送達ビヒクル、生体作用活性物質およびウイルスワクチン
WO2006078657A2 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
CA2610667A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
WO2007051036A2 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
US7914797B2 (en) 2005-12-06 2011-03-29 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Influenza vaccine
DK2478916T3 (da) * 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
TW200745158A (en) * 2006-03-07 2007-12-16 Vaxinnate Corp Compositions that include hemagglutinin, methods of making and methods of use thereof
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
WO2008002663A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
BRPI0815008B8 (pt) 2007-08-02 2021-05-25 Biondvax Pharmaceuticals Ltd vacinas multiméricas com múltiplos epítopos contra influenza
WO2009128949A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
EP3023107A1 (de) 2008-04-21 2016-05-25 Nanobio Corporation Nanoemulsions-influenza-impfstoff
EP2278994A4 (de) * 2008-04-25 2012-01-18 Inst Systems Biology Flagellin-polypeptid-vakzine
US8486619B2 (en) 2008-05-02 2013-07-16 University Of Rochester Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2590674B1 (de) 2010-07-06 2017-02-22 Variation Biotechnologies Inc. Zusammensetzungen und verfahren zur influenza-behandlung
EP2663327A4 (de) 2011-01-13 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013006797A1 (en) 2011-07-06 2013-01-10 Nanobio Corporation Human respiratory syncytial virus vaccine
CA2845872C (en) 2011-08-22 2023-03-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
EP2780350B1 (de) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetische mpl-derivate und ihre verwendung
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2013213345A1 (en) 2012-01-27 2014-08-28 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
RU2687026C2 (ru) 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
CN103961699B (zh) 2013-02-05 2018-11-06 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2840937A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
KR20140100415A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
CA2840974A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
KR102050931B1 (ko) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
EP2762161A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-enthaltende Impfstoffzusammensetzung zur mukosalen Verabreichung
EP2762157A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation Impfstoffzusammensetzung zur transdermalen oder mukosalen Verabreichung
RU2687144C2 (ru) 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения
RU2531235C2 (ru) * 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
WO2016035808A1 (ja) 2014-09-03 2016-03-10 日東電工株式会社 ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
CN106687127A (zh) 2014-09-03 2017-05-17 日东电工株式会社 含有双膦酸盐剂的体液免疫用疫苗药物组合物
WO2017022793A1 (ja) 2015-08-06 2017-02-09 日東電工株式会社 免疫誘導促進組成物及びワクチン医薬組成物
JP2020515283A (ja) 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
WO1997044667A2 (fr) * 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
IL143367A0 (en) 2002-04-21
US20070122424A1 (en) 2007-05-31
WO2000032228A3 (en) 2000-10-05
CA2352454A1 (en) 2000-06-08
DK2204187T3 (da) 2012-08-20
WO2000032228A2 (en) 2000-06-08
US7192595B2 (en) 2007-03-20
JP2002531415A (ja) 2002-09-24
ES2389611T3 (es) 2012-10-29
IL127331A0 (en) 1999-09-22
HK1145448A1 (en) 2011-04-21
US6740325B1 (en) 2004-05-25
NZ511918A (en) 2003-08-29
AU1406600A (en) 2000-06-19
HK1040620A1 (zh) 2002-06-21
EP2204187A1 (de) 2010-07-07
CA2352454C (en) 2013-02-05
EP1135159A2 (de) 2001-09-26
EP2204187B1 (de) 2012-05-09
KR100703571B1 (ko) 2007-04-05
KR20010089512A (ko) 2001-10-06
US7514086B2 (en) 2009-04-07
BR9915811A (pt) 2001-08-21
IL143367A (en) 2006-09-05
PT2204187E (pt) 2012-08-10
US20050002954A1 (en) 2005-01-06
AU766883B2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
ATE556719T1 (de) Impfstoff gegen menschliche influenza, der vier peptide aus influenza enthält
JP2002531415A5 (de)
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
RS51602B (sr) April receptor (bcma) i njegova upotreba
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ES2060603T3 (es) El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas.
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
GR1001550B (el) Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
CY1105763T1 (el) Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
Stryhn et al. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex.
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
TW200505943A (en) Polypeptide
Beauverger et al. Serotype-specific and canine distemper virus cross-reactive H-2Kk-restricted cytotoxic T lymphocyte epitopes in the measles virus nucleoprotein
BR0107175A (pt) Peptìdeos miméticos para epitopo de apolipoproteìna b-100, concatemero e seus peptìdeos modificados, e composição de vacina compreendendo os mesmos
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
ATE208421T1 (de) Stimulierung der immunantwort durch virales protein
RU2001113277A (ru) Регуляторные/развернутые пептиды эзрина
DK1073675T3 (da) Fremgangsmåde til omdannelse af echinocandinklassen af peptider til deres C4-homotyrosinmonodeoxyanaloger